Separator

Datafoundry: Accelerating Digital Transformation Journey in a Cost-effective and Secure Manner

Separator
Vivek Kalagara,  CEOBig data has been the buzzword for quite some time now in fact, the past decade witnessed a whopping rise in data generation from 1.2 trillion gigabytes to 59 trillion gigabytes. With that, the opportunities in this domain are far and wide,but only a few companies are efficiently equipped to leverage this digital gold and help companies fully capitalize on their resources. Among them, Datafoundry is a North Star that totally believes in the transformative power of data-driven AI to help clients extract optimum value from their data.

Under the able leadership of Vivek Kalagara(CEO), Narasimha Kumar(CPO), and Lakshmipathi Sattaru (COO) the team of experts in data science, AI/ML engineering, software development, cloud architecture, and domain knowledge is dedicated to improving the efficiency and effectiveness of business processes in the pharmaceutical and healthcare industries through innovative technology. “We offer the life sciences and healthcare sectors the best data science and automation-driven solutions to drive innovation and process excellence, ultimately leading to better health outcomes”, highlights Vivek Kalagara, CEO.

The founders of Datafoundry saw that datadriven business has become a complicated exercise and decided to help enterprises deal with data and analytics in an
optimal, cost-effective manner using best-in-class technologies. They started with executing data science related technology projects for global enterprises in life sciences and healthcare domains. The experience of executing these projects for life sciences companies, enabled Team Data foundry to embark upon building their own data and analytics platform and bring the power of AI/ML and Data Science for better health outcomes. “Data, AI, and life sciences integration are important components of our evolution into a mature version of ourselves,” the team remarks.

Unique & Acclaimed
Datafoundry uses advanced AI tools, including the proprietary MLP (Medical NLP) model called MediLP and OCR+NER technology, to help companies solve their biggest business challenges. “With a talented team experienced in all aspects of data transformation, AI labelling, and analytic services, we can help our customers save time and resources so that they can focus on meaningful work of improving health outcomes. Investing heavily in our AI capabilities sets us apart and enables us to deliver unparalleled value,” Vivek asserts.

He further adds, “Our approach has been two-fold to provide best-in-class data science related product engineering services to customers and to bring AI powered technology solutions to the life sciences and health care industry. Data foundry was established in 2016 and we started releasing our products into the market in 2020, and have seen a steady growth of product revenues since then. We are seeing increasing traction for our AI-powered products from Pharma, Cosmetics and CRO companies.”

Datafoundry has an exciting pipeline of innovative, AI-powered products for the Life Sciences industry. “Our DF Digitalize AI platform helps drug discovery, through clinical development, manufacturing, sales and regulatory compliance; it will further cater to various business functions within Life Sciences and Healthcare domain. In product engineering services, Data foundry will be entering into strategic partnerships with some market leading technology firms. The DF mSafety AI platform will pave the way for Data foundry to become a market leader in the Cosmetovigilance space. Our product DF mLiterature AI, which automates Literature Review and Monitoring of Medical and Scientific literature is being implemented at a major research institute in Australia and a global consumer pharma company, providing us anchor customers to penetrate strongly into this niche business segment. In addition, we have plans to introduce a fully AI powered Real World Data (RWD) solution to enable efficient design and conduct of clinical trials using real time data from Electronic Health Records, Wearables and Social Media”, they concluded.